Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study

Despite significant progress in melanoma survival, therapeutic options are still needed in case of progression under immune checkpoint inhibitors (ICI), and resistance to targeted therapies (TT) in BRAF-mutated melanomas. This study aimed to assess the safety of combined ICI and TT as a rescue line...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, Sandra, Mortier, Laurent, Dutriaux, Caroline, Maubec, Eve, Boileau, Marie, Dereure, Olivier, Leccia, Marie-Therese, Arnault, Jean-Philippe, Brunet-Possenti, Florence, Aubin, Francois, Dreno, Brigitte, Beylot-Barry, Marie, Lebbe, Celeste, Lefevre, Wendy, Delyon, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352575/
https://www.ncbi.nlm.nih.gov/pubmed/32585901
http://dx.doi.org/10.3390/cancers12061666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352575/
https://www.ncbi.nlm.nih.gov/pubmed/32585901
http://dx.doi.org/10.3390/cancers12061666

Ejemplares similares